240 related articles for article (PubMed ID: 23341861)
21. A critical role for neutralizing-antibody-producing B cells, CD4(+) T cells, and interferons in persistent and acute infections of mice with lymphocytic choriomeningitis virus: implications for adoptive immunotherapy of virus carriers.
Planz O; Ehl S; Furrer E; Horvath E; Bründler MA; Hengartner H; Zinkernagel RM
Proc Natl Acad Sci U S A; 1997 Jun; 94(13):6874-9. PubMed ID: 9192659
[TBL] [Abstract][Full Text] [Related]
22. Suppression of Antitumor Immune Responses by Human Papillomavirus through Epigenetic Downregulation of CXCL14.
Cicchini L; Westrich JA; Xu T; Vermeer DW; Berger JN; Clambey ET; Lee D; Song JI; Lambert PF; Greer RO; Lee JH; Pyeon D
mBio; 2016 May; 7(3):. PubMed ID: 27143385
[TBL] [Abstract][Full Text] [Related]
23. Tumor-associated macrophages, nanomedicine and imaging: the axis of success in the future of cancer immunotherapy.
Zanganeh S; Spitler R; Hutter G; Ho JQ; Pauliah M; Mahmoudi M
Immunotherapy; 2017 Sep; 9(10):819-835. PubMed ID: 28877626
[TBL] [Abstract][Full Text] [Related]
24. Preservation and redirection of HPV16E7-specific T cell receptors for immunotherapy of cervical cancer.
Scholten KB; Schreurs MW; Ruizendaal JJ; Kueter EW; Kramer D; Veenbergen S; Meijer CJ; Hooijberg E
Clin Immunol; 2005 Feb; 114(2):119-29. PubMed ID: 15639645
[TBL] [Abstract][Full Text] [Related]
25. The Double-Edged Sword-How Human Papillomaviruses Interact With Immunity in Head and Neck Cancer.
Wang HF; Wang SS; Tang YJ; Chen Y; Zheng M; Tang YL; Liang XH
Front Immunol; 2019; 10():653. PubMed ID: 31001266
[TBL] [Abstract][Full Text] [Related]
26. [Preventive vaccines and immunotherapy clinical trials against cervical cancer].
Valdespino-Gómez VM
Cir Cir; 2005; 73(1):57-69. PubMed ID: 15888272
[TBL] [Abstract][Full Text] [Related]
27. Human Papilloma Virus and Autophagy.
Mattoscio D; Medda A; Chiocca S
Int J Mol Sci; 2018 Jun; 19(6):. PubMed ID: 29914057
[TBL] [Abstract][Full Text] [Related]
28. Tim-3-expressing macrophages are functionally suppressed and expanded in oral squamous cell carcinoma due to virus-induced Gal-9 expression.
Dong J; Cheng L; Zhao M; Pan X; Feng Z; Wang D
Tumour Biol; 2017 May; 39(5):1010428317701651. PubMed ID: 28466780
[TBL] [Abstract][Full Text] [Related]
29.
Cheng Y; Lemke-Miltner CD; Wongpattaraworakul W; Wang Z; Chan CHF; Salem AK; Weiner GJ; Simons AL
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33060147
[TBL] [Abstract][Full Text] [Related]
30. Gearing up T-cell immunotherapy in cervical cancer.
Chauhan SR; Bharadwaj M
Curr Probl Cancer; 2018; 42(2):175-188. PubMed ID: 29776594
[TBL] [Abstract][Full Text] [Related]
31. The immune microenvironment in vulvar (pre)cancer: review of literature and implications for immunotherapy.
Abdulrahman Z; Kortekaas KE; De Vos Van Steenwijk PJ; Van Der Burg SH; Van Poelgeest MI
Expert Opin Biol Ther; 2018 Dec; 18(12):1223-1233. PubMed ID: 30373410
[TBL] [Abstract][Full Text] [Related]
32. The need for improvement of the treatment of advanced and metastatic cervical cancer, the rationale for combined chemo-immunotherapy.
van Meir H; Kenter GG; Burggraaf J; Kroep JR; Welters MJ; Melief CJ; van der Burg SH; van Poelgeest MI
Anticancer Agents Med Chem; 2014 Feb; 14(2):190-203. PubMed ID: 24237223
[TBL] [Abstract][Full Text] [Related]
33. STING expression and response to treatment with STING ligands in premalignant and malignant disease.
Baird JR; Feng Z; Xiao HD; Friedman D; Cottam B; Fox BA; Kramer G; Leidner RS; Bell RB; Young KH; Crittenden MR; Gough MJ
PLoS One; 2017; 12(11):e0187532. PubMed ID: 29135982
[TBL] [Abstract][Full Text] [Related]
34. hrHPV E5 oncoprotein: immune evasion and related immunotherapies.
de Freitas AC; de Oliveira THA; Barros MR; Venuti A
J Exp Clin Cancer Res; 2017 May; 36(1):71. PubMed ID: 28545552
[TBL] [Abstract][Full Text] [Related]
35. Identificaiton of Novel Immunogenic Human Papillomavirus Type 16 E7-Specific Epitopes Restricted to HLA-A*33;03 for Cervical Cancer Immunotherapy.
Kim S; Chung HW; Kong HY; Lim JB
Yonsei Med J; 2017 Jan; 58(1):43-50. PubMed ID: 27873494
[TBL] [Abstract][Full Text] [Related]
36. Emerging Opportunities and Challenges in Cancer Immunotherapy.
Whiteside TL; Demaria S; Rodriguez-Ruiz ME; Zarour HM; Melero I
Clin Cancer Res; 2016 Apr; 22(8):1845-55. PubMed ID: 27084738
[TBL] [Abstract][Full Text] [Related]
37. Potential use of lymph node-derived HPV-specific T cells for adoptive cell therapy of cervical cancer.
van Poelgeest MI; Visconti VV; Aghai Z; van Ham VJ; Heusinkveld M; Zandvliet ML; Valentijn AR; Goedemans R; van der Minne CE; Verdegaal EM; Trimbos JB; van der Burg SH; Welters MJ
Cancer Immunol Immunother; 2016 Dec; 65(12):1451-1463. PubMed ID: 27619514
[TBL] [Abstract][Full Text] [Related]
38. Immunotherapy for human papillomavirus-associated disease and cervical cancer: review of clinical and translational research.
Lee SJ; Yang A; Wu TC; Hung CF
J Gynecol Oncol; 2016 Sep; 27(5):e51. PubMed ID: 27329199
[TBL] [Abstract][Full Text] [Related]
39. Protective cancer immunotherapy: what can the innate immune system contribute?
Schmitz F; Heit A
Expert Opin Biol Ther; 2008 Jan; 8(1):31-43. PubMed ID: 18081535
[TBL] [Abstract][Full Text] [Related]
40. Coinfection with Epstein-Barr Virus (EBV), Human Papilloma Virus (HPV) and Polyoma BK Virus (BKPyV) in Laryngeal, Oropharyngeal and Oral Cavity Cancer.
Drop B; Strycharz-Dudziak M; Kliszczewska E; Polz-Dacewicz M
Int J Mol Sci; 2017 Dec; 18(12):. PubMed ID: 29257122
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
